Indicaton

Tucatinib is an investigational oral, potent, small molecule tyrosine kinase inhibitor that is highly selective for HER2 and is in a pivotal registration trial in HER2+ metastatic breast cancer.

Therapeutic indications
Type of product
Table
  • Phase

    Phase II started

  • Partnering status

    Not partnered